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Although global clinical trials for lung cancer can enable the development of new agents efficiently, whether the results of clinical trials
performed in one population can be fully extrapolated to another population remains questionable. A comparison of phase III trials
for the same drug combinations against lung cancer in different countries shows a great diversity in haematological toxicity. One
possible reason for this diversity may be that different ethnic populations may have different physiological capacities for white blood
cell production and maturation. In addition, polymorphisms in the promoter and coding regions of drug-metabolising enzymes (e.g.,
CYP3A4 and UGT1A1) or in transporters (e.g., ABCB1) may vary among different ethnic populations. For example, epidermal
growth factor receptor (EGFR) inhibitors are more effective in Asian patients than in patients of other ethnicities, a characteristic that
parallels the incidence of EGFR-activating mutations. Interstitial lung disease associated with the administration of gefitinib is also more
common among Japanese patients than among patients of other ethnicities. Although research into these differences has just begun,
these studies suggest that possible pharmacogenomic and tumour genetic differences associated with individual responses to
anticancer agents should be carefully considered when conducting global clinical trials.
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Lung cancer is the most common malignancy worldwide.
Approximately 1.2 million people are diagnosed with lung cancer
annually (accounting for 12.3% of all cancers); the second most
common malignancy is breast cancer (10.4%), followed by
colorectal cancer (9.4%). As lung cancer almost invariably has a
poor prognosis, it is the largest single cause of death from cancer
in the world, with a mortality of 1.1 million annually (Stewart and
Kleihues, 2003). Only 15% of lung cancer patients have a disease
that is confined to the lung and are candidates for surgical
resection; most patients with this disease have distant metastases
or pleural effusion at the time of their initial diagnosis. These
patients can be treated with systemic chemotherapy, but the
efficacy of currently available anticancer agents is limited and
patients with advanced diseases rarely live long.
As the development of new anticancer agents and chemother-
apeutic regimens is both time and money consuming, clinical trials
need to be as efficient as possible. One effort in this direction has
been the adoption of global clinical trials for new agents that involve
trial centres on more than one continent; this strategy enables
adequate sample sizes to be obtained in a relatively short-time period
and eliminates the need for redundant clinical trials with similar
objectives conducted in different countries. However, whether the
results of clinical trials performed in one population can be fully
extrapolated to other populations remains questionable because of
potential differences in trial designs, study-specific criteria, patient
demographics, frequency of monitoring, and population-related
pharmacokinetics, pharmacodynamics and pharmacogenomics.
Recently, these genetic and physiologic factors influencing cancer
chemotherapy have been increasingly examined and reported.
CLINICAL OBSERVATIONS OF TOXICITY DURING
CYTOTOXIC CHEMOTHERAPY
A comparison of phase III trials for the same drug combinations
against non-small cell lung cancer conducted in different countries
shows a great diversity in toxicity (Sekine et al, 2006). Among
trials studying the combination of carboplatin and paclitaxel, the
dose of carboplatin was fixed in all the trials, but the dose of
paclitaxel was 200mgm
 2 in Japanese and European trials and
225mgm
 2 in American trials. Grades 3–4 neutropenia was noted
in 88% of the patients in the Japanese trial, 15–51% of the patients
in the European trials, and 6–65% of the patients in the American
trials. Meanwhile, grades 3–4 febrile neutropenia was encountered
in 16% of the patients in the Japanese trial, 0–9% of the patients in
the European trials, and 2–4% of the patients in the American
trials (Table 1). For combinations of cisplatin and docetaxel
(Table 1) and cisplatin and vinorelbine (Table 2), the incidences of
grades 3–4 neutropenia and febrile neutropenia were almost the
same between phase III trials performed in different areas, but the
doses of docetaxel and vinorelbine in the Japanese trials were
lower than those in the European and American trials. Thus,
neutropenia in patients receiving a combination of platinum and
antimicrotubule agents may be more severe in Japanese than in
Europeans and Americans. A higher frequency of grades 3–4
neutropenia in Japanese patients than in American patients was
associated with combinations of cisplatin and irinotecan (65 vs
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for the treatment of extensive small-cell lung cancer (Lara et al,
2007).
How can this ethnic difference in the severity of neutropenia be
explained? One possibility is that the physiological capacity of the
white blood cell production and maturation may vary among
different ethnic populations. An asymptomatic reduction in
neutrophils (benign neutropenia) is more commonly observed
in individuals of African descent than in Caucasians, and no data
on this phenomenon are available for Asians (Hsieh et al, 2007).
The mechanisms are unclear, but a lower bone marrow reserve, an
intrinsic marrow difference, an abnormal cytokine response, or
any combination of these factors have been suggested (Hsieh et al,
2007). The lower neutrophil counts were associated with higher
levels of IL-8 and granulocyte colony-stimulating factor in African
volunteers. Thus, these cytokines are considered to compensate for
the relatively low neutrophil counts in this population (Mayr et al,
2007). A recent report showed that ethnicity-related low neutrophil
counts were associated with neutrophil elastase (ELA2)
polymorphisms (C-199A), but not with serum cytokine levels
(Grann et al, 2007).
ETHNIC DIFFERENCES IN DRUG METABOLISING
ENZYMES
An explanation for the ethnic differences in haematological
toxicity may be the varying activities of drug-metabolising
enzymes and transporters that are mainly associated with
polymorphisms in the promoter and coding regions of these
enzymes (Fujita and Sasaki, 2007). The haematological toxicity of
docetaxel monotherapy was associated with the clearance of this
agent in Asian patients, a phenomenon that can be largely
explained by CYP3A4 activity (Yamamoto et al, 2000). A study
conducted in the Netherlands showed that docetaxel clearance was
associated with the homozygous C1236T polymorphism in the
ABCB1 (p-glycoprotein) gene (ABCB1*8) but was not associated
with any CYP3A4 gene polymorphisms (Bosch et al, 2006). In
contrast, docetaxel pharmacokinetics were not associated with the
percent decrease in neutrophil counts nor with any poly-
morphisms in the CYP3A4 and ABCB1 genes in American patients
(Lewis et al, 2007). Another example of ethnic differences in drug-
metabolising enzymes is the association between polymorphisms
in genes involved in irinotecan metabolism and irinotecan-
induced neutropenia. Among the patients who received irinotecan
with or without another anticancer agent, grade 4 neutropenia was
noted in 40–57% of the patients with UDP-glucuronosyltransfer-
ase (UGT) 1A1*28 (a polymorphism in the promoter region of the
UGT1A1 gene) homozygosity, whereas neutropenia was only
observed in 15% or less of the patients with wild-type alleles. This
association was consistent in both Asian and Caucasian patients,
although the frequency of homozygosity was about 10% in
Caucasians and much lower in Asians. The UGT1A1*6 allele is
another polymorphism at exon 1 that is associated with defective
glucuronidating function and is found almost exclusively in Asian
individuals with a frequency as high as 20% (Fujita and Sasaki,
2007). UGT1A1*6 is significantly linked to polymorphisms of
UGT1A7 and UGT1A9. A haplotype including UGT1A1*6 and
UGT1A7*3, noted in as many as 15% of Japanese patients, and
UGT1A1*6 homozygosity, noted in 7% of Korean patients, were
significantly associated with decreased glucuronosyltransferase
activity for SN-38 and severe neutropenia (Han et al, 2006; Fujita
Table 1 Toxicity associated with a combination of platinum and taxane
Chemotherapy dose Grades 3–4 toxicity (%)
Research group Platinum Taxane No. of patients NP FNP Reference
A combination of carboplatin and paclitaxel
Japan 6 (AUC) 200 (mgm
 2) 145 88 16 Ohe et al (2007)
Greece 6 (AUC) 200 (mgm
 2) 252 15 0 Kosmidis et al (2002)
EU 6 (AUC) 200 (mgm
 2) 309 51 4 Rosell et al (2002)
ECOG 6 (AUC) 225 (mgm
 2) 290 63 4 Schiller et al (2002)
SWOG 6 (AUC) 225 (mgm
 2) 206 57 2 Kelly et al (2001)
SWOG 6 (AUC) 225 (mgm
 2) 182 — 3 Gandara et al (2004)
USA 6 (AUC) 225 (mgm
 2) 190 65 — Belani et al (2005)
USA 6 (AUC) 225 (mgm
 2) 345 6 — Herbst et al (2004)
A combination of cisplatin and docetaxel
Japan 80 (mgm
 2)6 0 ( m g m
 2) 151 74 2 Ohe et al (2007)
ECOG 75 (mgm
 2)7 5 ( m g m
 2) 289 69 11 Schiller et al (2002)
USA 75 (mgm
 2)7 5 ( m g m
 2) 408 75 5 Fossella et al (2003)
NP, neutropenia; FNP, febrile neutropenia.
Table 2 Toxicity associated with a combination of cisplatin and vinorelbine
Chemotherapy dose (mgm
 2) Grades 3–4 toxicity (%)
Research group Cisplatin Vinorelbine No. of patients NP FNP Reference
Japan 80 (day 1) 25 (days 1, 8) 145 88 18 Ohe et al (2007)
Greece 80 (day 8) 30 (days 1, 8) 204 37 11 Georgoulias et al (2005)
France 100 (day 1) 30 (weekly) 156 83 22 Pujol et al (2005)
EU 120 (day 1) 30 (weekly) 206 79 4 Le Chevalier et al (1994)
SWOG 100 (day 1) 25 (weekly) 202 76 1 Kelly et al (2001)
USA 100 (day 1) 25 (weekly) 404 79 5 Fossella et al (2003)
NP, neutropenia; FNP, febrile neutropenia.
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including chemotherapy, a homozygous or double heterozygous
genotype for UGT1A1*6 and UGT1A1*28 (*6/*6, *28/*28 or *6/
*28) was significantly associated with severe neutropenia (Minami
et al, 2007). In addition, patients with a homozygous C3435T
polymorphism in the ABCB1 gene are four-fold more likely to
develop grade 3 diarrhoea when treated with a combination of
cisplatin and irinotecan (Lara et al, 2007).
Data on associations between polymorphisms in genes coding
drug-metabolising enzymes and therapeutic efficacy remain
scarce. A recent prospective study in 250 patients with metastatic
colorectal cancer showed a significantly higher response rate (67 vs
40%) and a nonsignificant survival advantage (hazard ratio (HR):
0.81; 95% confidence interval (CI): 0.45–1.44) in patients
homozygous for UGT1A1*28, compared with those with wild-type
alleles; these outcomes were associated with a higher exposure to
SN-38 (Toffoli et al, 2006). In a study of 81 NSCLC patients, those
who were homozygous for UGT1A1*6 had a lower response rate
(0 vs 50%, P¼0.038) and a poorer MST (7.6 vs 17.7 months,
P¼0.017) as well as greater toxicities than the other patients (Han
et al, 2006). The most plausible explanation for the negative effects
of UGT1A1*6 on treatment outcome may be that the dose intensity
or cycle number might have been reduced in patients with
UGT1A1*6 because of polymorphism-associated toxicities (Fujita
and Sasaki, 2007).
These pharmacogenetic analyses have been rather preliminary.
Data on genotyping, pharmacokinetics, and pharmacodynamics
collected from a large number of patients with different ethnic
backgrounds are needed to demonstrate the cause of ethnic
differences in chemotherapy-associated toxicity.
EFFICACY OF EPIDERMAL GROWTH FACTOR
RECEPTOR TYROSINE KINASE INHIBITORS
Epidermal growth factor receptor (EGFR), a cell membrane
receptor with tyrosine kinase activity, is expressed in most patients
with NSCLC and plays a role in cellular proliferation, inhibition of
apoptosis, angiogenesis, metastatic potential, and chemoresis-
tance. Small-molecule inhibitors of EGFR, such as gefitinib and
erlotinib, have shown antitumor activity and have alleviated
symptoms in NSCLC patients who were previously treated with
standard chemotherapy. Two randomized phase II studies, IDEAL
(Iressa Dose Evaluation in Advanced Lung Cancer)-1 (involving
210 patients and conducted in Europe, Australia, South Africa, and
Japan) and IDEAL-2 (involving 216 patients and conducted in the
USA), have evaluated the efficacy of gefitinib at a dose of either
250mg daily or 500mg daily in patients with advanced NSCLC in
whom earlier platinum-based chemotherapy had failed. No
difference in the response rates between the doses was noted,
but an increased response rate was recorded for never smokers,
women, and those with an adenocarcinoma histology, compared
with patients who did not have these characteristics. In addition,
the response rate was 28% in Japanese patients but only 9–12% in
patients of other ethnicities (Fukuoka et al, 2003; Kris et al, 2003).
A randomized phase III trial, ISEL (Iressa Survival Evaluation in
Lung Cancer), of gefitinib vs a placebo in 1692 NSCLC patients
who had been previously treated with one or two chemo-
therapeutic regimens failed to show any survival benefit of
gefitinib; in the overall population, the median survival times
(MSTs) in the gefitinib and placebo arms were 5.6 and 5.1 months,
respectively (HR: 0.89; 95% CI: 0.78–1.03). A subgroup analysis,
however, showed that the MST was longer in Asian patients
receiving gefitinib than in those receiving the placebo (MST: 9.5 vs
5.5 months; HR: 0.66; 95% CI: 0.48–0.91). Similar results were seen
for never smokers: patients receiving gefitinib survived longer than
those receiving the placebo (MST: 8.9 vs 6.1 months; HR: 0.67, 95%
CI: 0.49–0.91) (Thatcher et al, 2005).
A similar association between objective responses and ethnicity
was observed in studies on erlotinib monotherapy for previously
treated advanced NSCLC. In an American phase II trial of this
agent in 57 advanced NSCLC patients with disease progression or
relapse after platinum-based chemotherapy, the response rate was
12% and the MST was 8.4 months (Perez-Soler et al, 2004). In
contrast, the combined data of two Japanese phase II trials of
erlotinib in similar patient populations showed objective responses
in 30 of 106 (28%) patients and an MST of 13.8 months. Among the
responders, significantly higher proportions of females (50%) than
males (17%) (P¼0.0009) and of never smokers (51%) than
smokers (14%) were observed (Po0.0001) (Tamura et al, 2007). A
phase III trial of erlotinib or a placebo in 731 NSCLC patients
previously treated with one or two chemotherapy regimens showed
that the response rate in Asian patients was higher than that
in patients of other ethnicities (28 vs 10%, P¼0.02) (Shepherd
et al, 2005).
These results of phases II and III trials consistently suggest that
EGFR tyrosine kinase inhibitors may be more effective in Asian
patients than in patients of other ethnicities.
In April 2004, the activating mutations of the EGFR gene were
identified in NSCLC specimens, and cancers with these mutations
were reported to be highly sensitive to gefitinib. The populations
with higher responses to gefitinib (females, non-smokers and
patients with an adenocarcinoma histology) also have higher
incidences of EGFR mutations (Kosaka et al, 2004; Pao et al, 2004;
Shigematsu et al, 2005). The incidence of EGFR mutations in
surgically resected tissue samples is summarised in Table 3
(Kosaka et al, 2004; Pao et al, 2004; Marchetti et al, 2005; Qin et al,
2005; Shigematsu et al, 2005; Soung et al, 2005; Tokumo et al, 2005;
Yang et al, 2005; Sasaki et al, 2006). The incidence varies from one
report to another, but EGFR mutations tend to be more common
among patients with an adenocarcinoma histology and among
non-smokers. Among Asian patients, the average incidences of
EGFR mutations were 31% overall, 47% among patients with
adenocarcinoma, and 56% among non-smokers; among other
ethnic populations, however, the average incidences were 7–8%
overall, 13–15% among patients with adenocarcinoma, and
34–35% among non-smokers (Table 3). Thus, the percentage of
responders to gefitinib or erlotinib almost paralleled the percen-
tage of patients with EGFR mutations.
The mechanism responsible for the high frequency of EGFR
mutations in Asian patients is a subject of great interest, and
polymorphisms in the regulatory sequence of the EGFR gene have
been vigorously investigated. The CA simple sequence repeat 1
(CA-SSR1), a highly polymorphic locus containing 14–21 CA
dinucleotide repeats, is located at the 50 end of intron 1 of the
EGFR gene. Studies of CA-SSR1 repeat length and EGFR
expression in breast cancer tissues have shown a constant decline
in EGFR expression with increasing repeat length (Buerger et al,
2000, 2004). In addition, a shorter repeat length was associated
with an elevated risk of lung cancer (Zhang et al, 2007) and poor
survival in NSCLC patients (Dubey et al, 2006). The CA-SSR1
repeat length distribution varies according to ethnicity, with
Asians tending to have longer repeats than Americans (Liu et al,
2003). Two single-nucleotide polymorphisms in the promoter
region of the EGFR gene ( 219G/T and  191C/A) were also
associated with promoter activity and EGFR expression (Liu et al,
2005), and their polymorphic types (associated with low EGFR
expression) were more common among Asians than among other
ethnicities (Nomura et al, 2007). These observations suggest that
many Asians have polymorphic types that lead to a decreased
intrinsic production of EGFR protein. If a certain critical level of
EGFR is required to drive the cell toward a malignant phenotype,
another mechanism including activating mutations of EGFR and/
or the autonomous activation of downstream signalling may be
required for the development of lung cancer among Asians
(Nomura et al, 2007).
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GEFITINIB AND ERLOTINIB
The frequencies of grades 3–4 common toxicities after the
administration of gefitinib, including diarrhoea, skin rash, and
elevated liver transaminase levels, have been similar among study
populations, but the incidence of severe interstitial lung disease
(ILD) associated with the administration of gefitinib differs
between patients in Japan and those in other countries. In the
IDEAL studies, two Japanese patients developed grades 3–4 ILD
(2%), whereas no patients outside of Japan experienced ILD
(Fukuoka et al, 2003; Kris et al, 2003). A retrospective study of
1976 consecutive patients treated with gefitinib at 84 institutions
showed that the incidence of ILD was 3.5% and the mortality rate
was 1.6%. Several risk factors for the development of gefitinib-
induced ILD were identified in the Japanese population: a history
of pulmonary fibrosis, a history of smoking, a poor performance
status, and a male sex (Ando et al, 2006). A similar incidence of
ILD (4.6%) was also noted in association with erlotinib
chemotherapy in Japanese phase II trials (Tamura et al, 2007).
The association between ILD and anticancer treatment is a
major topic in Japan because (1) the diagnosis of ILD can
be difficult and a consensus among physicians is sometimes
not reached, (2) the risk factors for ILD have not been fully
established, 3) an effective treatment for ILD has not been
established and the condition is often fatal, and (4) the low
frequency of this complication makes it difficult to conduct
pertinent clinical trials. Gefitinib-induced ILD seems to be more
common among Japanese patients than among other patients, but
the reasons for this ethnic difference are totally unknown.
CONCLUSION
The findings discussed here suggest that considerable variations in
the toxicity and efficacy of anticancer agents may exist among
patients of different ethnicities. Although research into these
differences has just begun, these studies suggest that possible
pharmacogenomic and tumour genetic differences associated with
individual responses to anticancer agents should be carefully
considered when conducting global clinical trials.
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